Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 117976-90-6] Rabeprazole sodium

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-B0656A
Brand:	MCE
CAS:	117976-90-6

Overview

MDL	MFCD02092688
Molecular Weight	381.42
Molecular Formula	C18H20N3NaO3S
SMILES	O=S(C1=NC2=CC=CC=C2N1[Na])CC3=NC=CC(OCCCOC)=C3C

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Front Immunol. 2022 Jun 21;13:895869.

Summary

Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor ( PPI ) that irreversibly inactivates gastric H ⁺ /K ⁺ -ATPase. Rabeprazole sodium induces apoptosis . Rabeprazole sodium acts as an uridine nucleoside ribohydrolase ( UNH ) inhibitor with an IC ₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux ^[1] ^[2] ^[3] .

IC50 & Target

Pump inhibitor (PPI) ^[1]
IC50: 0.3 μM (UNH) ^[1]
H ⁺ /K ⁺ -ATPase ^[2]
Apoptosis ^[2]

In Vitro

Rabeprazole attenuates the cell viability of the human gastric cancer cells following treatment with 0.2 mM for 16 hours ^[2] .
Rabeprazole completely inhibits the phosphorylation of ERK1/2 in the MKN-28 cells. The gastric cancer cell line MKN-28 is cultured in acidic culture media (pH 5.4) for 2 hours. Pretreatment with Rabeprazole (0.2 mM for 2 hours) leads to strong inhibition of ERK 1/2 phosphorylation in the MKN-28 cells ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[2]

Cell Line:	Three gastric cancer cell lines KATO III, MKN-28 and MKN-45
Concentration:	0.2 mM
Incubation Time:	16 hours
Result:	Treatment resulted in the attenuation of viability in all cancer cell lines tested, the cell viability of the MKN-28 cells significantly decreased compared with the KATO III and MKN-45 cells, respectively.

Western Blot Analysis ^[2]

Cell Line:	Three gastric cancer cell lines (KATO III, MKN-28 and MKN-45) ^[2]
Concentration:	0.2 mM
Incubation Time:	Pretreatment for 2 hours
Result:	Led to strong inhibition of ERK 1/2 phosphorylation in the MKN-28 cells, but a similar effect was not observed in the KATO III and MKN-45 cells.

In Vivo

Rabeprazole (10 mg/kg; P.O.; every 48 h for 18 weeks) course leads to a significant decline in bone mineral density (BMD) and decreases serum calcium level and produces secondary hyperparathyroidism in female mice ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Swiss albino mice (body weight equals 18-26 g) ^[3]
Dosage:	10 mg/kg
Administration:	Oral administration; every 48 h for 18 weeks
Result:	Showed significantly lower serum calcium level compared to the vehicle treated group (5.5±2.07 vs. 9.68±2.77).

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00287391	University of North Carolina\|Janssen Pharmaceutica N.V., Belgium\|University of North Carolina, Chapel Hill	Insomnia\|GERD	September 2004	Phase 4
NCT01398046	University of California, San Francisco\|Genentech, Inc.	Healthy	August 2011	Phase 1
NCT00216489	Janssen Cilag Pharmaceutica S.A.C.I., Greece	Gastroesophageal Reflux\|Heartburn	March 2003	Phase 4
NCT01321567	Eisai Co., Ltd.\|Eisai Inc.	Refractory Reflux Esophagitis	January 1, 2011
NCT04471922	Sihuan Pharmaceutical Holdings Group Ltd.	Healthy Volunteers	March 21, 2019	Phase 1
NCT00658528	Eisai Inc.	Gastroesophageal Reflux Disease (GERD)	February 2008	Phase 3
NCT05330858	Alumis Inc	Pharmacokinetics	March 17, 2022	Phase 1
NCT00214552	Associated Scientists to Help Minimize Allergies\|Janssen Pharmaceuticals\|Eisai Inc.	Asthma\|Gastroesophageal Reflux Disease	September 2002	Phase 3
NCT05018923	Shanghai Zhongshan Hospital	Helicobacter Pylori Infection	August 24, 2021	Phase 4
NCT03290703	Genentech, Inc.	Healthy Volunteers	April 18, 2017	Phase 1
NCT04489797	AstraZeneca\|Acerta Pharma BV	Infectious Disease	July 20, 2020	Phase 1
NCT00787891	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.\|Eisai Inc.	Gastroesophageal Reflux Disease (GERD)	January 2009	Phase 3
NCT01101646	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Gastroesophageal Reflux	August 2008	Phase 1
NCT01918176	Pfizer	Healthy	September 2013	Phase 1
NCT01954043	GlaxoSmithKline	Cancer	December 20, 2013	Phase 1
NCT01008696	Janssen Korea, Ltd., Korea	Reflux Esophagitis	May 2007	Phase 4
NCT00165841	Eisai Inc.	Gastroesophageal Reflux Disease	October 2004	Phase 2
NCT00162877	National Taiwan University Hospital	Peptic Ulcer With H. Pylori Infection\|Gastritis With H. Pylori Infection	June 2004	Not Applicable
NCT01772290	Genentech, Inc.	Healthy Volunteer	February 2013	Phase 1
NCT00911534	Eisai Inc.	Symptomatic Gastroesophageal Reflux Disease (sGERD)	January 2009	Phase 3
NCT01277718	Genentech, Inc.	Healthy Volunteer	January 2011	Phase 1
NCT01408186	Chinese University of Hong Kong	Upper Gastrointestinal Bleeding	January 2011	Phase 3
NCT03908619	Changi General Hospital	Helicobacter Pylori Infection	April 16, 2019	Phase 4
NCT00839306	Eisai Inc.	Gastroesophageal Reflux Disease (GERD)	August 2008	Phase 3
NCT00251732	University of Arizona\|Southern Arizona VA Health Care System\|Janssen Pharmaceutica N.V., Belgium	Gastroesophageal Reflux Disease	March 2005	Phase 4
NCT05014685	Shanghai Zhongshan Hospital	Helicobacter Pylori Infection	August 20, 2021	Phase 4
NCT03464058	Boston Pharmaceuticals	Healthy Subjects	March 21, 2018	Phase 1
NCT00747526	Janssen Research & Development, LLC\|Eisai Inc.	Gastroesophageal Reflux Disease (GERD)	December 2007	Phase 1
NCT04211545	Celgene	Healthy Volunteer	October 21, 2019	Phase 1
NCT01202071	Eisai Co., Ltd.\|Eisai Inc.	Healthy	September 2010	Phase 2
NCT02097329	Pfizer	Healthy	April 2014	Phase 1
NCT00999128	Genentech, Inc.	Healthy Volunteers	October 26, 2009	Phase 1
NCT01241409	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Healthy	October 2010	Phase 1
NCT01140828	Chinese University of Hong Kong	Osteoarthritis\|Arthritis, Rheumatoid\|Dyspepsia	May 2009	Phase 3
NCT00861640	Kaohsiung Medical University Chung-Ho Memorial Hospital\|Kaohsiung Medical University	Nonvariceal Upper Gastrointestinal Bleeding	March 2009	Phase 4
NCT00838682	The Catholic University of Korea\|Janssen Korea, Ltd., Korea	Peptic Ulcer Hemorrhage	April 2006	Phase 4
NCT01085708	Eisai Co., Ltd.\|Eisai Inc.	Healthy	April 2010	Phase 1
NCT01264822	Eisai Co., Ltd.\|Eisai Inc.	Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive	January 13, 2011
NCT01037491	Taipei Veterans General Hospital, Taiwan	Gastric Ulcer\|Duodenal Ulcer	October 2009	Not Applicable
NCT04565574	Eisai Co., Ltd.\|Eisai Inc.	Healthy Participants	October 16, 2020	Phase 1
NCT04494243	Addpharma Inc.	Gastroesophageal Reflux Disease	August 28, 2020	Phase 1
NCT00517270	Hospital Authority, Hong Kong\|The University of Hong Kong	Chest Pain	March 2003	Not Applicable
NCT00649493	Mylan Pharmaceuticals Inc\|MylanPharma	Healthy	May 2003	Phase 1
NCT00199953	Medical College of Wisconsin\|Ortho-McNeil, Inc.\|Eisai Inc.	Postnasal Drainage	June 2002	Phase 2
NCT00216450	Janssen Cilag Pharmaceutica S.A.C.I., Greece	Helicobacter Infections\|Bacterial Infections	October 2004	Phase 4
NCT00517114	Hospital Authority, Hong Kong\|The University of Hong Kong	Gastroesophageal Reflux\|Laryngitis	January 2005	Not Applicable
NCT04645940	Hutchison Medipharma Limited\|Hutchmed	Drug Interaction\|Food-drug Interaction	September 24, 2020	Phase 1
NCT01286194	Eisai Inc.	Frequent Heartburn	April 2006
NCT03658473	Galeno Desenvolvimento de Pesquisas Clínicas\|Biolab Sanus Farmaceutica	Gastric Lesion	November 12, 2014	Phase 3
NCT01990586	Torrent Pharmaceuticals Limited	Healthy		Phase 1
NCT00658632	Eisai Inc.	Gastroesophageal Reflux Disease (GERD)	February 2008	Phase 3
NCT00844675	The Catholic University of Korea\|Janssen Korea, Ltd., Korea	Early Gastric Adenocarcinoma\|Adenocarcinoma, Tubular	October 2007	Phase 4
NCT05023577	Shanghai Zhongshan Hospital	Helicobacter Pylori Infection	August 26, 2021	Phase 4
NCT00992589	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.\|Eisai Inc.	Gastroesophageal Reflux	November 2009	Phase 3
NCT01018160	Janssen Korea, Ltd., Korea	Gastroesophageal Reflux	June 2008
NCT02826408	Jordan Collaborating Cardiology Group	Signs and Symptoms	October 2016	Not Applicable
NCT00234117	Ponce Gastroenterology Research\|PriCara, Unit of Ortho-McNeil, Inc.	Bronchial Asthma\|Gastroesophageal Reflux	July 2005	Not Applicable
NCT01699113	Trio Medicines Ltd.	Hypergastrinaemia	August 2006	Phase 1
NCT02475161	Janssen Research & Development, LLC	Healthy	June 2015	Phase 1
NCT02463643	Zeria Pharmaceutical	Esophagitis, Reflux	May 2015	Phase 2
NCT04215653	Sihuan Pharmaceutical Holdings Group Ltd.	Duodenal Ulcer?DU	January 20, 2020	Phase 3
NCT03237741	Genentech, Inc.\|Quotient Clinical	Amyotrophic Lateral Sclerosis	August 7, 2017	Phase 1
NCT03320538	Jiangxi University of Traditional Chinese Medicine\|Jiangxi Hospital of Traditional Chinese Medicine\|The First Affiliated Hospital of Nanchang University\|Second Affiliated Hospital of Nanchang University\|The Third Affiliated Hospital of Nanchang University\|Nanchang Hongdu Hospital of Traditional Chinese Medicine\|Nanchang Hospital of Integrated Traditional Chinese and Western Medicine\|The Nanchang Third Hospital\|Xinyu People´s Hospital\|Xinyu Hospital of Traditional Chinese Medicine\|Jiujiang No.1 People´s Hospital\|Jiujiang Hospital of Traditional Chinese Medicine	Peptic Ulcer Disease	July 10, 2017	Not Applicable
NCT01504971	Chinese PLA General Hospital	Gastroesophageal Reflux Disease	January 2011
NCT01398410	Eisai Co., Ltd.\|Eisai Inc.	Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin	December 2011	Phase 2\|Phase 3
NCT04132479	Kirby Institute\|University of Medicine 2, Yangon, Myanmar	Helicobacter Pylori Infection	January 1, 2018	Phase 4
NCT00658775	Eisai Inc.	Gastroesophageal Reflux Disease (GERD)	February 2008	Phase 3
NCT02986685	Xijing Hospital of Digestive Diseases\|Ankang City Central Hospital\|Shaanxi Provincial People´s Hospital\|Baoji Central Hospital\|Hanzhong Central Hospital	Refractory Reflux Esophagitis	November 2016	Phase 4
NCT04503629	Sihuan Pharmaceutical Holdings Group Ltd.	Duodenal Ulcer?DU	October 9, 2018	Phase 2
NCT01237353	University of California, San Francisco	Pharmacodynamic	March 2011	Not Applicable
NCT01089543	Eisai Co., Ltd.\|Eisai Inc.	Functional Dyspepsia	April 2010	Phase 2
NCT00614536	Janssen Korea, Ltd., Korea	Gastroesophageal Reflux\|Pharyngeal Diseases	September 2007
NCT00838526	Eisai Inc.	Gastroesophageal Reflux Disease (GERD)	August 31, 2008	Phase 3
NCT00125736	Eisai Co., Ltd.\|Eisai Inc.	Stomach Ulcer	August 1, 2005	Phase 4
NCT01922765	The Catholic University of Korea\|Bucheon St. Mary´s Hospital\|St Vincent´s Hospital	Gastritis, Gastric Ulcer, and Duodenal Ulcer	August 2013	Phase 4
NCT04001400	Seoul National University Hospital\|IlDong Pharmaceutical Co Ltd	Esophageal Disease	October 10, 2012	Phase 3
NCT04157881	Population Health Research Institute\|Hamilton Health Sciences Corporation	Atrial Fibrillation\|Venous Thromboembolism	January 3, 2020	Phase 4
NCT00553449	Janssen-Ortho Inc., Canada	Gastroesophageal Reflux\|Heartburn	July 2004	Phase 3
NCT01085695	Eisai Co., Ltd.\|Eisai Inc.	Healthy	April 2010	Phase 1
NCT05380947	Boehringer Ingelheim	Healthy	June 23, 2022	Phase 1
NCT00222170	University of Kansas\|PriCara, Unit of Ortho-McNeil, Inc.\|Eisai Inc.\|University of Kansas Medical Center	Esophageal Reflux	May 2005	Phase 2
NCT02311946	Pfizer	Healthy	January 2015	Phase 1
NCT05446142	Pfizer\|Ono Pharmaceutical Co. Ltd\|Pierre Fabre Laboratories	Healthy	July 1, 2022	Phase 1
NCT00236184	Eisai Inc.	Heartburn	October 2005	Phase 3
NCT01139645	American University of Beirut Medical Center\|AstraZeneca	Calcium Metabolism Disorders	October 2009	Not Applicable
NCT02524210	Centre Hospitalier Universitaire de Saint Etienne	Healthy	May 2014	Phase 1
NCT03979248	Bristol-Myers Squibb	Healthy	May 16, 2019	Phase 1
NCT00378287	Janssen-Ortho Inc., Canada	GERD	October 2005	Phase 1
NCT00236392	Janssen Pharmaceutica N.V., Belgium	Gastroesophageal Reflux\|Heartburn	October 2001	Phase 3
NCT01153659	Eisai Inc.	Healthy	July 2010	Phase 1
NCT01391715	Inje University	Gastroesophageal Reflux Disease	August 2011	Phase 3
NCT00304421	VA Greater Los Angeles Healthcare System\|PriCara, Unit of Ortho-McNeil, Inc.\|Eisai Inc.	Gastroesophageal Reflux Disease	January 2004	Phase 4
NCT02655614	Genentech, Inc.	Amyotrophic Lateral Sclerosis	May 31, 2016	Phase 1
NCT00855361	Janssen Research & Development, LLC\|Eisai Inc.	Gastroesophageal Reflux	July 2009	Phase 1
NCT04944771	AstraZeneca\|Parexel	Solid and Hematological Malignancies	July 26, 2021	Phase 1
NCT00354757	National Taiwan University Hospital	GERD	June 2005	Phase 4
NCT05604261	Xuanzhu Biopharmaceutical Co., Ltd.	Reflux Esophagitis\|Gastroesophageal Reflux\|Esophagitis\|Esophageal Motility Disorders\|Deglutition Disorders\|Esophageal Diseases\|Gastrointestinal Diseases	December 2022	Phase 2
NCT05571787	Hutchmed	Relapsed or Refractory Lymphoma	July 13, 2022	Phase 1
NCT00511966	Janssen-Cilag, S.A.	Gastroesophageal Reflux
NCT02847455	Livzon Pharmaceutical Group Inc.	Duodenal Ulcer	August 2008	Phase 2\|Phase 3
NCT01287091	Genentech, Inc.	Healthy Volunteer	October 2010	Phase 1
NCT01990378	Torrent Pharmaceuticals Limited	Healthy		Phase 1
NCT00236197	Eisai Inc.	Heartburn	October 2005	Phase 3
NCT02569554	Pfizer	Healthy	December 2015	Phase 1
NCT02699710	Genentech, Inc.	Healthy Volunteer	September 3, 2015	Phase 1
NCT05419674	Second Affiliated Hospital, School of Medicine, Zhejiang University	Helicobacter Pylori Infection	June 15, 2022	Phase 4
NCT01186497	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Healthy	August 2010	Phase 1
NCT03789032	Akebia Therapeutics	Drug Interaction Potentiation\|Pharmacokinetics	October 3, 2018	Phase 1
NCT00747695	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.\|Eisai Inc.	GERD	March 2008	Phase 1
NCT00648349	Mylan Pharmaceuticals Inc\|MylanPharma	Healthy	May 2003	Phase 1
NCT04703868	Yungjin Pharm. Co., Ltd.\|Seoul National University Hospital	Gastroesophageal Reflux Disease	January 13, 2021	Phase 1
NCT00132496	Eisai Inc.	Gastroesophageal Reflux Disease	August 2005	Phase 2
NCT02509923	Zeria Pharmaceutical	Healthy	July 2015	Phase 1
NCT02037477	Takeda	Healthy Volunteers	January 2014	Phase 3
NCT02135107	Eisai Co., Ltd.\|Eisai Inc.	Gastroesophageal Reflux Disease	September 2013	Phase 3
NCT00165672	Eisai Inc.\|Eisai Limited	Non-erosive Gastroesophageal Reflux Disease	May 2005	Phase 3
NCT00539240	US Department of Veterans Affairs\|VA Office of Research and Development	Gastroesophageal Reflux Disease	April 2006	Phase 2\|Phase 3
NCT01136317	Nantes University Hospital	Gastroesophageal Reflux	April 2010	Phase 2
NCT00464308	Janssen-Cilag Pty Ltd	Gastro-oesophageal Reflux	November 2006	Phase 4
NCT04564612	Biogen	Healthy Volunteers	September 28, 2020	Phase 1
NCT01759875	University of California, San Francisco	Healthy	January 2013	Phase 1
NCT05014334	Xijing Hospital of Digestive Diseases	Helicobacter Pylori Infection\|Chronic Gastritis	December 1, 2021	Phase 4
NCT03130556	Pfizer	Healthy Volunteers	May 1, 2017	Phase 1
NCT01857609	Seoul National University Hospital	Healthy	August 2012	Phase 1
NCT04667299	Shanghai Zhongshan Hospital	Helicobacter Pylori Infection	December 20, 2020	Phase 4
NCT02555852	Canadian Network for Observational Drug Effect Studies, CNODES\|Drug Safety and Effectiveness Network, Canada\|Canadian Institutes of Health Research (CIHR)	Gastroesophageal Reflux Disease (GERD)\|Community-acquired Pneumonia	September 2011
NCT00237367	PriCara, Unit of Ortho-McNeil, Inc.\|Eisai Inc.	Gastroesophageal Reflux		Phase 4
NCT05602597	Hutchmed	HMPL-689 Drug Interaction Study	June 1, 2022	Phase 1
NCT03802318	Chang Gung Memorial Hospital	Helicobacter Pylori Infection\|Helicobacter Gastritis\|Helicobacter-Associated Pyloric Ulcer	January 2, 2019	Not Applicable
NCT02638584	Il-Yang Pharm. Co., Ltd.	Gastric Cancer	December 2015	Phase 4
NCT00681005	National Taiwan University Hospital	GERD	April 2006	Not Applicable
NCT01513785	Shanghai Jiao Tong University School of Medicine	Functional Dyspepsia	April 2011	Phase 2
NCT04622358	Addpharma Inc.	Gastroesophageal Reflux Disease	December 5, 2020	Phase 1
NCT05061732	Shanghai Zhongshan Hospital	Helicobacter Pylori Infection	September 30, 2021	Phase 4
NCT03530995	Kadmon Corporation, LLC\|Quotient Sciences	Drug-drug Interaction\|Autoimmune Diseases\|Fibrotic Disease	April 9, 2018	Phase 1
NCT00220857	Temple University	Normal Subjects	September 2005	Phase 4
NCT03134378	Indonesia University	Helicobacter Pylori Infection	October 3, 2016	Phase 4
NCT03220191	Pfizer	Healthy Volunteer	July 21, 2017	Phase 1
NCT04697186	Xijing Hospital of Digestive Diseases	Dyspepsia\|Chronic Gastritis\|Gastric Cancer\|Helicobacter Pylori Infection	January 7, 2021	Phase 4
NCT00989300	Janssen Cilag S.A.S.	Healthy	November 2009	Phase 1
NCT00649194	Mylan Pharmaceuticals Inc\|MylanPharma	Healthy	August 2003	Phase 1
NCT00539786	Samsung Medical Center	Gastroesophageal Reflux Disease	March 2006	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility

In Vitro:

H ₂ O : ≥ 100 mg/mL ( 262.18 mM )

DMSO : ≥ 48 mg/mL ( 125.85 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6218 mL	13.1089 mL	26.2178 mL
5 mM	0.5244 mL	2.6218 mL	5.2436 mL
10 mM	0.2622 mL	1.3109 mL	2.6218 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (5.45 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Tara A Shea, et al. Identification of Proton-Pump Inhibitor Drugs That Inhibit Uridine Nucleoside Ribohydrolase. Bioorg Med Chem Lett. 2014 Feb 15;24(4):1080-4.
[2] Mengli Gu, et al. Rabeprazole Exhibits Antiproliferative Effects on Human Gastric Cancer Cell Lines. Oncol Lett. 2014 Oct;8(4):1739-1744.
[3] Aly A M Shaalan, et al. Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels. Front Pharmacol. 2020 May 13;11:583.

Synonyms

1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt (1:1)

1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt

E 3810

LY 307640 sodium

Rabeprazole sodium

Pariprazole

Pariet

Aciphex

2-[[[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methyl]sulfinyl]-1H-benzimidazole sodium salt

Rabicip

Pepcia

Razo

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart